The Utility of Breast Cancer Index (BCI) Over Clinical Prognostic Tools for Predicting the Need for Extended Endocrine Therapy: A Safety Net Hospital Experience

Shah, Sachin; Shaing, Christine; Khatib, Jude; Lodrigues, William; Dreadin-Pulliam, Julie; Anderson, Bryana B.; Unni, Nisha; Farr, Deborah; Li, Hsiao-Ching; Sadeghi, Navid; Syed, Samira

doi:10.1016/j.clbc.2022.08.003

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Breast Cancer Index (BCI) is a predictive test that can predict recurrence as well as indicate benefit from extended adjuvant ET [96][97][98][99]. The test incorporates 11 genes and can predict a patient's risk of distant recurrence up to 10 years after surgery.…”

Section: Breast Cancer Indexmentioning

confidence: 99%

The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer

Kay,

Martinez-Perez,

Dixon

et al. 2023

JPM

View full text Add to dashboard Cite

The majority of breast cancers are oestrogen receptor-positive (ER+). In ER+ cancers, oestrogen acts as a disease driver, so these tumours are likely to be susceptible to endocrine therapy (ET). ET works by blocking the hormone’s synthesis or effect. A significant number of patients diagnosed with breast cancer will have the spread of tumour cells into regional lymph nodes either at the time of diagnosis, or as a recurrence some years later. Patients with node-positive disease have a poorer prognosis and can respond less well to ET. The nodal metastases may be genomically similar or, as is becoming more evident, may differ from the primary tumour. However, nodal metastatic disease is often not assessed, and treatment decisions are almost always based on biomarkers evaluated in the primary tumour. This review will summarise the evidence in the field on ER+, node-positive breast cancer, including diagnosis, treatment, prognosis and predictive tools.

show abstract

Section: Breast Cancer Indexmentioning

confidence: 99%

The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer

Kay,

Martinez-Perez,

Dixon

et al. 2023

JPM

View full text Add to dashboard Cite

show abstract

Managing a Long and Winding Road: Estrogen Receptor–Positive Breast Cancer

Gnant

Turner

Hernándo

2023

American Society of Clinical Oncology Educational Book

View full text Add to dashboard Cite

We review key topics in the management of estrogen receptor (ER)–positive human epidermal growth factor receptor 2–negative breast cancer. The single biggest challenge in management of this disease is late relapse, and we review new methods for identifying which patients are at risk of late relapse and potential therapeutic approaches in clinical trials. CDK4/6 inhibitors have become a standard treatment option for high-risk patients in both the adjuvant setting and the first-line metastatic setting, and we review data on optimal treatment after progression on CDK4/6 inhibitors. Targeting the estrogen receptor remains the single most effective way of targeting the cancer, and we review the developments in new oral selective ER degraders that are becoming a standard of care in cancers with ESR1 mutations and potential future directions.

show abstract

The Utility of Breast Cancer Index (BCI) Over Clinical Prognostic Tools for Predicting the Need for Extended Endocrine Therapy: A Safety Net Hospital Experience

Cited by 2 publications

References 25 publications

The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer

The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer

Managing a Long and Winding Road: Estrogen Receptor–Positive Breast Cancer

Contact Info

Product

Resources

About